May help lower blood pressure and reduce the risk of heart disease
Key findings from the Phase 2 trial included: Dose-dependent weight loss , with greater reductions observed at higher doses Significant improvements in waist circumference , blood pressure , and lipid profiles Reductions in fasting glucose and insulin resistance markers, though the clinical significance of these findings in people with type 2 diabetes requires further investigation Weight loss appeared to continue throughout the 48-week period without a clear plateau at the highest doses Whilst these results are encouraging, it is important to contextualise them appropriately
Reduces Dark Spots and Pigmentation: Helps achieve a more even complexion
Theres no magic dose that works for everyone
Ultimately, your weight loss journey is a personal one, and your Shapely team will be by your side to help you achieve your best results Typically, we find that patients of our weight loss program in Princeton, Texas who are taking GLP-1 agonists such as Ozempic and Wegovy will lose 10% of weight by 6 months and 15% within 1 year
2015;9:p
